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Abstract
Purpose Brain metastases (BM) are an increasing clinical problem. This study aimed to assess paired primary breast cancers 
(BC) and BM for aberrations within TP53, PIK3CA, ESR1, ERBB2 and AKT utilising the MassARRAY® UltraSEEK® 
technology (Agena Bioscience, San Diego, USA).
Methods DNA isolated from 32 paired primary BCs and BMs was screened using the custom UltraSEEK® Breast Cancer 
Panel. Data acquisition and analysis was performed by the Agena Bioscience Typer software v4.0.26.74.
Results Mutations were identified in 91% primary BCs and 88% BM cases. TP53, AKT1, ESR1, PIK3CA and ERBB2 genes 
were mutated in 68.8%, 37.5%, 31.3%, 28.1% and 3.1% respectively of primary BCs and in 59.4%, 37.5%, 28.1%, 28.1% 
and 3.1% respectively of BMs. Differences in the mutations within the 5 genes between BC and paired BM were identified 
in 62.5% of paired cases. In primary BCs, ER-positive/HER2-negative cases harboured the most mutations (70%), followed 
by ER-positive/HER2-positive (15%) and triple-negatives (13.4%), whereas in BMs, the highest number of mutations was 
observed in triple-negative (52.5%), followed by ER-positive/HER2-negative (35.6%) and ER-negative/HER2-positive (12%). 
There was a significant association between the number of mutations in the primary BC and breast-to-brain metastasis-free 
survival (p = 0.0001) but not with overall survival (p = 0.056).
Conclusion These data demonstrate the discordancy between primary BC and BM, as well as the presence of clinically 
important, actionable mutations in BCBM. The UltraSEEK® Breast Cancer Panel provides a tool for BCBM that can be 
utilised to direct more tailored treatment decisions and for clinical studies investigating targeted agents.
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Introduction
Breast cancer brain metastasis (BCBM) is a growing clini-
cal problem associated with significant morbidity and 
mortality [1]. Up to 40–50% of women with HER2-posi-
tive and triple-negative breast cancers (BC) will develop 
brain metastasis (BM), whereas its incidence in hormone 
receptor-positive BC is 14% [2–5]. The application of 
next generation sequencing technologies has enabled the 
characterisation of BCs and highlighted that BC subtypes 
differ in their mutational profiles but overall, the common-
est mutated genes are TP53, PIK3CA, GATA3, CDH1, 
AKT1 [6–11]. Genomic profiling has also demonstrated 
the complex and diverse molecular landscapes of second-
ary metastatic BCs [7, 8, 11, 12]. BM sequencing studies 
have identified differences in their mutational landscape as 
compared to primary tumours [13–17]. The identification 
of genomic alterations within BM and the use of targeted 
therapies against these mutations may improve the clinical 
outcomes of patients with BCBM [10–17].
In the era of precision medicine and targeted therapies, 
the choice of anti-cancer therapy is increasingly tailored 
according to the molecular and/or genomic characterisa-
tion of the underlying malignancy. Identifying rare and 
low-level mutations due to tumour heterogeneity in cancer 
samples and/or of poor-quality DNA isolated from forma-
lin-fixed, paraffin-embedded (FFPE) tissues entails tools 
that offer both low-frequency detection and efficient use of 
starting material. Such tools could, in turn, be utilised for 
therapeutic decision making and/or development of clini-
cal trials using targeted agents. The UltraSEEK® (Agena 
Bioscience, San Diego, USA) technology provides a tar-
geted, multiplexed method for detecting rare events, with 
detection threshold as low as 0.1% on the MassARRAY® 
system utilising DNA isolated from FFPE tissues, plasma 
and cerebrospinal fluid [18–21]. Moreover, multiplex 
detection of low-frequency mutations is becoming a nec-
essary diagnostic tool for clinical laboratories that must 
overcome several challenges such as the detection of minor 
alleles among abundant wild-types, the heterogeneous 
nature of the tumours and the limited amount of available 
tissue [18–21]. The UltraSEEK® Breast Cancer panel has 
been developed to enable the assessment of five commonly 
mutated genes in breast cancer, TP53, PIK3CA, ERBB2, 
ESR1 and AKT1. This study aimed to assess the muta-
tional landscape of paired BC and BMs for these known 
key genomic drivers, utilising the UltraSEEK® BC panel.
Materials and methods
Patients
A total of 32 FFPE primary BC samples, with their paired 
BMs were collected from the Liverpool Tissue Bank and 
the Walton Research Tissue Bank (WRTB) Liverpool, UK. 
The cases were stained by immunohistochemistry (IHC) for 
hormone receptor expression (ER, PgR) and HER2 as previ-
ously described [22]. The study was performed in accord-
ance with the Declaration of Helsinki and approved by the 
WRTB (WRTB 15_06) and the National Research Ethics 
Committee (NRES 11/WN003/2). Written consent was in 
place before anonymised tissue and data were released for 
research purposes [22].
DNA extraction and mutation profiling
DNA was isolated from 32 BC and their matched BM cases 
using the GeneRead DNA FFPE kit (Qiagen, Crawley, UK) 
and screened using the custom UltraSEEK BC Panel (Agena 
Bioscience, San Diego, USA). Starting from a single global 
multiplex polymerase chain reaction (PCR) the panel tests 
39 mutations (Table 1) across 5 oncogenes (TP53, PIK3CA, 
Table 1  UltraSEEK breast cancer panel
The UltraSEEK BC panel screens for 39 mutations across 5 common BC oncogenes
*Multiple assays for these mutations are included in the panel
Genes Missense mutations No of 
muta-
tions
AKT1 pE17K٭, pL52R٭ 2
ERBB2 (HER2) pG309A, pG309E, pS310F٭, pL755R, pL755S,
pL755_T759del , pD769H٭, pD769Y, pV777L٭, pL869R٭
10
ESR1 pA283V, pK303R, pE380Q٭, pV392I, pS463P, pL536R, pL536Q, pY537C, pY537N٭, pY537S, 
pD538G, pS576L
12
PIK3CA pN345K, pC420R٭, pE542K٭, pE545A, pE545K٭, pE545Q, pH1047L٭, pH1047R 8
TP53 pR175H, pR213X, pY220C, pR248Q, pR248W٭, pR273C, pR273H 7
Total 5 genes 39
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ESR1, ERBB2 and AKT) in 8 multiplex assays (Supplemen-
tary table 1). The number of mutations was defined as the 
total number of mutations identified in any of the 5 genes 
per patient. The range of mutations is 0–39 (Table 1). PCR 
was performed using 10 ng of DNA according to the manu-
facturer’s instructions (Agena Bioscience, San Diego, USA). 
Amplified products were treated with shrimp alkaline phos-
phatase (SAP) and the PCR/SAP product was aliquoted in 
a new 96-well plate for downstream extension and termina-
tion reaction according to the manufacturer’s instructions. 
The single-base extended oligonucleotides were captured 
by streptavidin-coated magnetic beads and biotin-labelled 
following manufacturer’s instructions. The products were 
then transferred to the MassARRAY System with Chip Prep 
Module 96 (CPM96) that automatically performs desalting 
(resin), transfer of analyte and calibrant to the Spectro-
CHIP® Arrays and loading of SpectroCHIP® Arrays. Data 
were automatically acquired using the MassARRAY Ana-
lyzer. The workflow is presented and summarised in Sup-
plementary Fig. 1.
Data analysis and statistics
Data were analysed using the Typer software v4.0.26.74 
(Agena Bioscience, San Diego, USA). The signal intensity 
of the mutant allele was normalised against the capture-
control peaks (biotin-labelled, non-reactive oligos, used as 
an internal control) as previously reported [18, 19]. Sam-
ples with a mutant allele-call with a signal-to-noise ratio ≥ 6 
and a z-score ≥ 7 were considered positive for the mutation. 
Positive mutant-calls with z-scores 7–10 were labelled ‘L’ 
(low-level confidence) to distinguish from the results with 
high-level confidence (T), z-score > 10 [18–20]. The z-score 
is a robust scoring representing the deviation of the minor 
allele’s frequency from the median baseline frequency, as 
measured by median absolute deviation (MAD) units. The 
baseline signal distribution or population of that peak is 
generated by analysing a population of known wild-type 
samples for each target and capture pre-analytical and back-
ground noise inherent to the assay and analyte. The Ultra-
SEEK chemistry and methodology has been analytically 
presented by Mosko et al. [19].
RAWGraphs (https:// rawgr aphs. io/) was used to gener-
ate the alluvial diagram illustrating the receptor switching 
between the primary and metastatic setting. Fisher’s Exact 
test was used to compare the receptor status change versus 
the number of mutations (≤ 3 vs > 3) in the primary BC and 
Wilcoxon signed-rank paired t test (Gaussian approxima-
tion) was used to compare the total number of mutations 
between the paired BC and BMs. Kaplan–Meier (Log-rank) 
survival analysis was used to determine whether the num-
ber of mutations in the primary BC and the receptor sta-
tus change between BCs and BMs was associated with the 
breast–brain metastasis-free survival (BMFS, time between 
the initial breast surgery and the resection of the BM) and 
overall survival (OS, time between breast diagnosis/surgery 
and death from any cause). Given the range of mutations 
seen in primary breast cancer samples was 0–5 and to enable 
the greatest contrast within the studied population an arbi-
trary cut-off of > 3 mutations was chosen following an analy-
sis of groups based on 0–1, 2–3 and 4–5 (> 3) mutations in 
the primary breast cancer (Supplementary Fig. 2). Statistical 
analysis was performed on GraphPad Prism v5.0 (GraphPad 
Inc, San Diego, USA).
The OncoKB (http:// oncoKB. org) and ClinicalTrials.
gov (https:// clini caltr ials. gov) databases were used to iden-
tify actionability and ongoing clinical trials on BC using 
targeted therapies for the mutated genes in this study. The 
searches on OncoKB were performed for Breast Cancer, 
Actionable Genes and the following Levels of Evidence: 
1. FDA-approval, 2. Standard care, 3. Clinical evidence, 4. 
Biological evidence, R1/R2. Resistance. The searches on 
the ClinicalTrials.gov were performed for Breast Cancer, 
Recruiting, Active (not recruiting), Completed, Adult and 
selecting for specific gene mutations/alterations for PIK3CA, 
AKT1, ESR1, ERBB2/HER2 and TP53. Similar work on 
BCBM mutated genes was recently presented by our group 
in a systematic review [14].
Results
Patient characteristics and receptor switching
Among the 32 primary BCs, 18 (56.2%) were ER-positive/
HER2-negative, 4 (12.5%) were ER-positive/HER2-positive, 
3 (9.4%) were ER-negative/HER2-positive and 7 (21.9%) 
were triple-negative (TN). Eight of the 18 (44.4%) ER-pos-
itive and all the 4 (100%) ER-positive/HER2-positive pri-
mary BCs lost ER expression in BM. The HER2-positive 
and TN primary BCs maintained their receptor status in 
the BM. The changes of the receptor status between BCs 
and their paired BMs are illustrated in the alluvial diagram 
(Fig. 1A).
Mutational profiling of primary BCs and their paired 
BMs
A mutation in any of the five genes was identified in 29 of 
32 (90.6%) primary BCs and 28 of 32 (87.5%) BM cases. 
A total number of 67 and 59 mutations were detected in 
primary BCs and their paired BMs respectively without sig-
nificant association in the number of mutations between the 
paired BC and BM cases (p = 0.424, median 2 in both BC 
and BM, Fig. 1B). Out of the 32 paired BCs and BMs, TP53, 
AKT1, ESR1 and PIK3CA genes were respectively mutated 
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in 22 (68.8%), 12 (37.5%), 10 (31.3%) and 9 (28.1%) of the 
primary BCs and in 19 (59.4%), 12 (37.5%), 9 (28.1%) and 
9 (28.1%) of the BMs. ERBB2 mutations were detected in 
1 out of 32 (3.1%) BC and BM cases. The total number of 
mutations in each gene, including percentages, is illustrated 
in Fig. 1C and Supplementary table 2.
Differences in the number of mutations 
between primary BCs and their paired BMs
We observed that in 20 of 32 (62.5%) paired cases there 
were differences in the total number of mutations between 
the primary BC and paired BM with 11 of 32 (34.4%) and 9 
of 32 (28.1%) cases showing either a reduction or increase 
in the total number of mutations respectively in the paired 
BMs. In 12 of 32 (37.5%) paired cases the number of muta-
tions did not differ. The scatter-plot showing the number of 
mutation changes between pairs is illustrated in Fig. 1D. The 
genomic landscape of the paired BC and their BMs for the 
individual mutations and the confidence level of detection (T 
or L) for each one is presented in a matrix format in Fig. 2. 
We observed that 22/32 (68.75%) of patients lost or gained 
a mutation in the brain metastatic site in at least one of the 5 
clinically relevant genes (Fig. 2). Mutations were detected 
with similar confidence (T/T and/or L/L) in 18 of 32 (56.3%) 
paired BC and BM cases and increased to 21 of 32 (65.6%) 
when mutations with different confidence (L/T) between 
paired BC and BM cases were included, highlighting the dif-
ferences in the genomic landscape between primary BC and 
paired BM. For instance, the AKT1 pE17K mutation was 
detected in 10 of 32 (31.25%) paired cases; 8 of 32 (25%) 
with the same confidence levels and 2 of 32 (6.3%) cases 
with low confidence (L) in the primary and high confidence 
(T) in paired BM (Fig. 2). The TP53 pR273H was the more 
prevalent mutation in both BC and BM cases present in 4 
of 32 (12.5%) paired cases, 3 of which with similar confi-
dence and 1 with lower confidence in BC than BM (Fig. 2). 
Representative examples of the different mutation spectra 
highlighting the differences in the confidence levels (T/T, 
T/L, -/T) are presented in Fig. 3A. 
Mutations and receptor status change 
between primary BCs and their paired BMs
The 32 primary BCs contained a total of 67 mutations and 
hormone receptor-positive cases harboured the most muta-
tions (47/67; 70%), followed by ER-positive/HER2-positive 
(10/67; 15%) and triple-negatives (9/67; 13.4%), whereas 
in BMs with a total of 59 mutations, the highest number 
was observed in triple-negatives (31/59; 52.5%), followed 
by hormone receptor-positive (21/59; 35.6%) and HER2-
positive (7/59; 12%). Of the 32 primary BCs, 27 (84.37%) 
had 3 or less mutations (≤ 3) and 9 of these (33.3%) change 
status in BM, whereas 18 (66.7%) maintain their receptors. 
Of the 5 (15.63%) primary BCs with > 3 mutations, 3 (60%) 
change status in BM and 2 (40%) maintain their receptors. 
There was no significant association between the receptor 
switching and the number of mutations identified by two-
tail Fisher’s exact test (p = 0.337). The number of patients, 
the total number of mutations and the number of mutations 
in each gene according to the receptor status of BC and BM 
are presented in Supplementary table 2. All the mutation 
frequencies for the primary BCs and BMs according to the 
receptor status are illustrated in Fig. 3B.
Association of mutations with patient outcome
Patients with primary BCs with ≤ 3 mutations had a sig-
nificantly longer BMFS, than patients whose BCs had > 3 
mutations with median BMFS of 28.5 and 12  months 
respectively (p = 0.0001, HR: 0.011, 95% CI: 0.001–0.112, 
Fig. 3C). There was no association with OS although the 
median OS was 53 and 29 months in patients carrying ≤ 3 
and > 3 mutations respectively (p = 0.056, HR: 0.146, 95% 
CI: 0.020–1.054, Fig. 3C). Patients with differences in the 
numbers of mutations between primary BC and BM classi-
fied as mutation numbers increasing in BM versus mutation 
numbers decreasing in BM, showed a significant difference 
in the brain metastasis-death (time between brain metastasis 
and death due to any cause) survival outcome (p = 0.0008, 
HR: 17.72, 95% CI: 3.277–95.87, Supplementary Fig. 3).
When the patients were classified according to the change 
in ER, PgR and HER2 status between primary BC and BM 
the median BMFS was 24.5 (receptor change) and 29.5 (no 
change) (p = 0.115) months. No significant association was 
observed with OS (p = 0.618) either.
Potentially actionable targets
A search on oncoKB for the actionability of PIK3CA, 
AKT1, ESR1, and ERBB2/HER2 oncogenic mutations on 
BC identified 7 protocols, 3 of which are FDA-approved 
(Alpelisib, Neratinib and Abemaciclib. No protocols were 
identified for TP53 (Table 2).
Forty-three clinical trials are currently available for BC 
patients with mutations in these 5 genes as identified within 
ClinicalTrials.gov (Supplementary table 3), whereas twelve 
trials specifically recruiting patients with BCBM using tar-
geted therapies for the identified gene mutations/alterations 
were recently reported [14]. Drugs targeting PIK3CA [Pax-
alisib (GDC-0084), Buparlisib (BMK120)], ERBB2/HER2 
(Neratinib, Afatinib, Pyrotinib, Tucatinib), pathways and/or 
genes involved in the cell cycle (Abemaciclib, NKTR-102) 
are currently undergoing assessment in clinical trials either 
as single agents or in combination with standard of care 
treatments for BCBM [14].
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Table 2  OncoKB database and gene actionability




No of mutations (%) Drugs Citations
BC (N = 32) BM (N = 32)
1 PIK3CA 10 (15) 10 (17) Alpelisib + Fulvestrant 3 PI3K inhibition results in enhanced oestrogen recep-
tor function and dependence in hormone receptor-
positive breast cancer. Bosch A et al. Sci Transl 
Med. 2015 PMID: 25,877,889
Alpelisib Plus Fulvestrant in PIK3CA-Altered 
and PIK3CA-Wild-Type Oestrogen Receptor-
Positive Advanced Breast Cancer: A Phase 1b 
Clinical Trial. Juric D et al. JAMA Oncol. 2019 
PMID: 30,543,347
Alpelisib for PIK3CA -Mutated, Hormone 
Receptor-Positive Advanced Breast Cancer. André 
F et al. N Engl J Med. 2019 PMID: 31,091,374
3 GDC-0077 3 355TiP Phase III study of GDC-0077 or placebo 
(pbo) with palbociclib (P) + fulvestrant (F) in 
patients (pts) with PIK3CA-mutant/hormone 
receptor-positive/HER2-negative locally advanced 
or metastatic breast cancer (HR + /HER2– LA/
MBC). TurnerN et al. Annals Onc. 2020 
10.1016/j.annonc.2020.08.457
Juric D et al. Abstract# OT1-08–04, SABCS 2019
Hong R et al. Abstract# PD4-14, SABCS 2017
3 Copanlisib + Fulvestrant 7 First-in-human phase I study of copanlisib (BAY 
80–6946), an intravenous pan-class I phosphati-
dylinositol 3-kinase inhibitor, in patients with 
advanced solid tumours and non-Hodgkin's 
lymphomas. Patnaik A et al. Ann Oncol. 2016 
PMID: 27,672,108
Exceptional Response to Copanlisib in a Heavily 
Pretreated Patient With PIK3CA-Mutated Meta-
static Breast Cancer. Spathas N et al. JCO Prec 
Onc. 2020 10.1200/PO.19.00049
Staben et al. Abstract# DDT02-01, AACR 2017
De et al. Abstract# 3438, AACR 2019
O'Brien, NA et al. Abstract P3-04–15. Cancer 
Research, 2017
De et al. Abstract# P2-03–08, SABCS 2018
Edgar et al. Abstract# 156, AACR 2017
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Table 2  (continued)




No of mutations (%) Drugs Citations
BC (N = 32) BM (N = 32)
3 AKT1 12 (18) 12 (20.3) AZD5363 4 Preclinical pharmacology of AZD5363, an inhibitor 
of AKT: pharmacodynamics, antitumour activity, 
and correlation of monotherapy activity with 





an orally bioavailable, potent inhibitor of Akt 
kinases. Addie M et al. J Med Chem. 2013 
PMID: 23,394,218
AKT Inhibition in Solid Tumours With AKT1 
Mutations. Hyman DM et al. J Clin Oncol. 2017 
PMID: 28,489,509
Tumours with AKT1E17K Mutations Are Rational 
Targets for Single Agent or Combination Therapy 
with AKT Inhibitors. Davies BR et al. Mol Cancer 
Ther. 2015PMID: 26,351,323
1 ERBB2/HER2 1 (1.5) 1 (1.7) Neratinib 3 Activating HER2 mutations in HER2 gene amplifi-
cation negative breast cancer. Bose R et al. Cancer 
Discov. 2013 PMID: 23,220,880
The major lung cancer-derived mutants of ERBB2 
are oncogenic and are associated with sensitiv-
ity to the irreversible EGFR/ERBB2 inhibitor 
HKI-272. Minami Y et al. Oncogene. 2007 
PMID: 17,311,002
HER kinase inhibition in patients with HER2- 
and HER3-mutant cancers. Hyman DM 
et al. Nature. 2018 PMID: 29,420,467
Breast Cancer Research and Treatment 
1 3
Discussion
In this study, we assessed for the presence of mutations 
within key BC genes utilising the UltraSEEK® technol-
ogy in a paired cohort of BCs and BMs. A mutation in at 
least one of the five genes (TP53, PIK3CA, ERBB2, ESR1, 
AKT1) was identified in most cases, with 90.6% of primary 
BC and 87.5% of the paired BMs having at least one muta-
tion. The observed similarities regarding the frequency of 
the mutated genes reflect the nature of the UltraSEEK® 
BC panel that was designed to target actionable genes pre-
sent in all the key BC subtypes. Twenty-two out of the 32 
patients in this study (68.75%), lost or gained a mutation 
in the brain metastatic site in at least one of the 5 clini-
cally relevant genes (Fig. 2) highlighting the importance of 
screening for mutations in the primary and metastatic site. 
The actionability of these mutated genes in primary BC 
and BM is presented in Table 2 and in a recent systematic 
review [14]. The detection of ESR1 mutations in the pri-
mary tumours also highlights the sensitivity of the assay 
[19]. Although ESR1 mutations were more commonly iden-
tified in metastatic BCs [23, 24], the use of the sensitive 
droplet-digital PCR reported higher frequencies in primary 
tumours [25, 26]. The identification of therapeutic strategies 
in breast cancers harbouring ESR1 mutants is an area of 
active interest. Fulvestrant has demonstrated poor clinical 
activity in ESR1-mutated BC [27, 28], whereas bazedox-
ifene and lasofoxifene have demonstrated activity in pre-
clinical models of ESR1-mutated BC [29, 30]. The efficacy 
of lasofoxifene is currently being explored in the ELAINE 
trial (NCT03781063) in patients with ESR1-mutated BCs 
(Supplementary table 3). Interestingly, in our cohort, ESR1 
Table 2  (continued)




No of mutations (%) Drugs Citations
BC (N = 32) BM (N = 32)
3 ESR1 13 (19.4) 11 (18.6) AZD9496 2 Efficacy of a novel orally active SERD AZD9496 
against hormone dependent post-menopausal 
breast cancer depends on inhibition of cellular 
aromatase activity. Kazi A et al. J Ster Biochem 
Mol Biol. 2020 ISSN: 0960–0760
A Randomised, Open-label, Presurgical, Window-
of-Opportunity Study Comparing the Pharma-
codynamic Effects of the Novel Oral SERD 
AZD9496 with Fulvestrant in patients with Newly 
Diagnosed ER + HER2 − Primary Breast Cancer. 
Robertson JFR et al. 2020 PMID: 32,234,755
1 Abemaciclib + Fulvestrant 4 Analysis of Overall Survival Benefit of Abemaciclib 
Plus Fulvestrant in Hormone Receptor–Posi-
tive, ERBB2-Negative Breast Cancer. Gil-Sierra 
MD et al. JAMA Oncol. 2020 10.1001/jamaon-
col.2020.1516
The Effect of Abemaciclib Plus Fulvestrant on 
Overall Survival in Hormone Receptor-Positive, 
ERBB2-Negative Breast Cancer That Progressed 
on Endocrine Therapy-MONARCH 2: A Ran-
domised Clinical Trial. Sledge GW Jr et al. JAMA 
Oncol. 2019 PMID: 31,563,959
Activating ESR1 Mutations Differentially Affect the 
Efficacy of ER Antagonists. Toy W et al. Cancer 
Discov. 2017 PMID: 27,986,707
Plasma ESR1 Mutations and the Treatment of 
Oestrogen Receptor-Positive Advanced Breast 
Cancer. Fribbens C et al. J Clin Oncol. 2016 
PMID: 27,269,946
NA TP53 31 (46.3) 25 (42.4)
Total no of mutations 67 59
A search on the oncoKB for the actionability of PIK3CA, AKT1, ESR1, ERBB2/HER2 and TP53 oncogenic mutations on breast cancer identi-
fied 7 protocols. 1. FDA-approval, 3. Clinical evidence
NA Not available
 Breast Cancer Research and Treatment
1 3
Fig. 1  Receptor switch and mutation detection in paired BC and 
BM samples. A The Alluvial diagram illustrates the receptor (ER, 
PgR, HER2) switch between primary BC and their paired BM cases 
including % for each subtype. B No significant association was iden-
tified (p = 0.484) in the number of mutations between primary BCs 
and their paired BMs. C Total number of mutations per gene identi-
fied in both BC (blue) and BM (red) samples. The percentage of each 
mutation over the total number of mutations is presented on the top 
of each bar and on supplementary table 3. D Scatter-plot showing the 
number of mutations for each pair. Blue dots-lines and red dots-lines 
represent the number of mutations changing between BC and from 
BM. Black dots represent the cases with similar number of mutations 
in both the primary BC and its paired BM
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mutations were seen in 28.1% of BMs despite the loss of ER 
expression by IHC, indicating that the ESR1-mutant clones 
are likely dominant clones, resistant to therapy [23–26, 28]. 
These results are in accordance with others who detected a 
high ESR1 mutation frequency (34.3–44.9%) in BMs [25].
While TP53 is mutated in all BC subtypes, it is most 
common in TNs and HER2 [4, 31–33]. TP53 mutations 
have been associated with worse clinical outcomes and poor 
response to hormonal therapy, chemotherapy and/or radio-
therapy [31–34] and our samples have been acquired from 
patients who had progressed and developed brain metastasis 
despite prior treatment. TP53 can be re-activated by target-
ing molecules that modulate its posttranslational modifi-
cations, localisation and degradation and several ongoing 
clinical trials are using TP53-reactivating compounds in 
combination with chemotherapeutic drugs (Supplementary 
table 3) [35, 36].
ERBB2/HER2 mutations were identified in only 2 sam-
ples, a primary ER-positive BC and a HER2-positive BM. 
These ERBB2/HER2 mutations are associated with resist-
ance to lapatinib but are sensitive to neratinib, highlighting 
the importance of treating HER-mutated cancers with the 
appropriate HER-targeted drugs (Table 2, Supplementary 
table 3) [37, 38]. The identification of mutations in PIK3CA 
and AKT1 are also of clinical significance since both genes 
are druggable (Table 2, Supplementary table 3). The PI3Kα-
specific inhibitor alpelisib, has shown activity in PIK3CA-
mutant breast cancers (NCT02437318) and recently granted 
FDA and European commission approval, while its potential 
in the regression and stabilisation of progressive BCBM has 
been highlighted [39, 40]. The brain-penetrant inhibitor pax-
alisib (GDC-0084) has demonstrated activity in pre-clinical 
models of BCBM [41]. Several inhibitors targeting the 
AKT1 pE17K mutation, an oncogenic driver in BC, have 
shown efficacy as monotherapy or in combination with other 
drugs (Table 2, Supplementary table 3) [42–44]. We recently 
presented a summary of current clinical trials on mutated 
BCBMs [14].
Several studies have identified large similarities in the 
mutational profiles of primary tumours and their metasta-
ses including BMs [6–11], whereas others showed clear 
differences between primary and metastasis in the numbers 
and types of mutations [12–15]. It was recently suggested 
that the systemic metastatic seeding can begin early during 
primary tumour growth and that the clonal architecture is 
remodelled by treatment that may select for disseminated 
cells harbouring resistant mutations [45]. Treatment was 
also associated with high gene heterogeneity and monoclo-
nal metastases [45]. Similarly, within our cohort of paired 
BC and BM cases, the median BMFS time (irrespectively 
of mutation status) was 26 months and certain gene muta-
tions were detected with similar confidence levels in 56.3% 
of paired cases (monoclonal metastases). We also identified 
cases where the mutation was absent or present with low 
confidence in the primary and with high confidence in the 
BM and vice versa. This is clinically relevant as the identi-
fication of mutations especially with low intensity (low con-
fidence levels) in the primary could indicate the presence of 
clones that could drive the metastatic process or be responsi-
ble for treatment-resistance and present therefore with higher 
intensity (high confidence levels) in the metastatic site. Tar-
geting these mutations early, in the primary disease with the 
appropriate drugs could possibly prevent the development of 
metastatic disease. Similarly, the absence of mutations in the 
Fig. 2  The genomic landscape of BCBM using the UltraSEEK Breast 
Cancer Panel. The illustrated matrix presents paired BC and BM 
patients IDs, the genes with the identified mutations, the multiplex 
assays (purple indicates that 2 assays were run for these mutations) 
and the confidence call of the mutations. T (green): High level confi-
dence call = high signal intensity and z-score > 10, L (red): Low level 
confidence call = low signal intensity and z-score 7–10. The total 
number of mutations, the breast–brain metastasis-free (BMFS) and 
the overall survival (both in months) and the receptor status are also 
presented. * Synchronous, NA Not available
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primary tumour that are present in the metastatic site (low 
or high) is of clinical relevance as these mutations should be 
targeted with the appropriate therapeutic regimens aimed at 
the brain metastatic site. The fact that only 37.5% of muta-
tions in the 5 chosen genes are conserved between the pri-
mary and just one major metastatic site, the brain, suggests 
that, in general, compounds targeting these mutations identi-
fied solely in the primary breast tumour are unlikely to be 
successful in the majority of advanced/metastatic patients. 
Therefore, it seems to be necessary to sample metastases, 
as well as the primary tumour to identify somatic mutations 
to tumours at both sites, to predict more accurately whether 
a patient will respond to such chemical interventions. The 
differences in the mutational landscape could be attributed to 
the clonal evolution process, the selective pressure of differ-
ent therapeutic regimens and the receptor switching between 
primary BC and metastasis. Evidence of clonal remodelling 
between primary tumours and metastases associated with 
the clinical subtype conversion was recently presented, but 
the most frequently mutated genes in primary tumours were 
also identified in metastases independent of the tumour sub-
type [12]. We did not observe significant differences in the 
frequently mutated genes in relation to the subtypes in BC 
and BM and there was no significant association between 
receptor switching and number of mutations. This could 
also be attributed to the small number of genes present in 
the targeted BC mutation panel and the small number of 
mutations identified in our cohort. Nevertheless, within our 
cohort, patients carrying ≤ 3 mutations had a significantly 
better BMFS (p = 0.0001), than patients with > 3 mutations 
indicating that the higher number of mutations correlates to 
worst prognosis (metastasis-free survival).
A limitation of the MassARRAY UltraSEEK technol-
ogy and therefore, a limitation of this study, in compari-
son to next generation sequencing on the identification of 
mutations is the use of predefined mutations across differ-
ent oncogenes. Although, it cannot detect unknown muta-
tions and copy number alterations, it is more cost-effective 
and could be easier applied in a clinical setting [21, 46, 
47]. Another limitation is the number of paired samples in 
the study, although it is higher that the number of paired 
BCBM samples reported in other genomic studies [14]. 
The challenges to obtain BM samples for sequencing 
including the inherent risks of neurosurgery, as samples 
can only be taken when surgical resection is clinically 
indicated, make longitudinal studies of the changes in the 
BM genome unethical. The increasing use of stereotactic 
surgery (SRS) has reduced the need for surgical resection 
but also, the availability of tissue. The alternative use of 
circulating cell-free DNA (cfDNA) in the CSF and plasma 
is under investigation and in the future patients will be 
able to have tailored treatments based on the results of 
sequencing cfDNA from CSF rather than relying on the 
genomics of the primary lesion [20, 46, 47]. Nevertheless, 
these data complement the current literature as it high-
lights the presence of actionable mutations in clinically 
important genes both in BC and BM identified by a sensi-
tive, targeted, comprehensible technology, potentially use-
ful in a routine clinic. The fact that the limited number of 
mutations detected and the change in the number of muta-
tions in the metastatic site correlate to survival outcomes 
reinforces the importance of patient mutation screening.
In summary, our data highlight the presence of clini-
cally important and actionable mutations in AKT1, ESR1, 
PIK3CA, TP53 and ERBB2 genes in BC and in BCBM 
as identified by the UltraSEEK BC panel that provides a 
powerful tool to investigate low abundance mutations and 
could be potentially useful in a clinical environment [25, 
26]. These mutations could be used to identify patients 
resistant to certain therapeutic regimens and enable the 
development of more tailored clinical studies utilising tar-
geted agents or combinations of them in the brain meta-
static setting.
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relative intensity on the y-axis and mass/charge on the x-axis. B The 
frequency (percentages) of the identified mutations for each of the 5 
genes according to the ER, PgR and HER2 receptor status in primary 
BC and in paired BM. The exact number of mutations is presented 
in Supplementary Table 4. One of the 3 ER-negative/HER2-positive 
primary BC samples was carrying an ESR1 mutation, whereas no 
mutations were identified in the other 2 samples and they were not 
included in the pie-charts. C Kaplan–Meier (Log-rank) survival plots 
of breast–brain metastasis-free survival (BMFS) and overall survival 
(OS). Patients carrying ≤ 3 mutations had a significantly better BMFS 
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95% CI: 0.020–1.054) and number of mutations
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